Boston Scientific Finalizes Terms for $14.71B Penumbra Acquisition, Details Shareholder Vote

summarizeSummary

Boston Scientific has filed a definitive proxy statement/prospectus for its $14.71 billion acquisition of Penumbra, Inc., detailing the cash and stock consideration for Penumbra shareholders and setting the date for the shareholder vote.

check_boxKey Events

• Definitive Merger Terms Filed

  Boston Scientific filed the definitive proxy statement/prospectus for its approximately $14.71 billion acquisition of Penumbra, Inc., initially announced on January 15, 2026.

• Merger Consideration Details

  Penumbra shareholders can elect to receive $374.00 in cash or 3.8721 Boston Scientific shares per Penumbra share, subject to proration, with the total consideration split approximately 73.26% cash and 26.74% stock.

• Stock Consideration Value Decline

  The value of the stock consideration per Penumbra share has decreased from $374.00 at announcement (January 14, 2026) to $267.83 as of March 27, 2026, based on Boston Scientific's closing price.

• Shareholder Dilution and Financing

  Boston Scientific expects to issue approximately 43,866,267 shares, resulting in former Penumbra shareholders owning approximately 2.87% of Boston Scientific post-merger. The $11 billion cash component will be funded by existing cash and new debt facilities.

auto_awesomeAnalysis

This filing provides the definitive proxy statement/prospectus for Boston Scientific's substantial $14.71 billion acquisition of Penumbra, Inc., a significant strategic move to expand its medical technology portfolio. The deal involves a mix of cash and stock consideration for Penumbra shareholders, with a notable 2.87% dilution for existing Boston Scientific shareholders. The receipt of an FTC Second Request and Boston Scientific's commitment to litigate and potentially divest up to $300 million in revenue indicate significant regulatory hurdles and potential costs or delays. Furthermore, the value of the stock consideration has decreased since the initial announcement, which could impact Penumbra shareholders electing stock. This transaction, occurring while Boston Scientific's stock is trading near 52-week lows, represents a major financial and operational undertaking with inherent risks.